JP2018518151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518151A5 JP2018518151A5 JP2017550485A JP2017550485A JP2018518151A5 JP 2018518151 A5 JP2018518151 A5 JP 2018518151A5 JP 2017550485 A JP2017550485 A JP 2017550485A JP 2017550485 A JP2017550485 A JP 2017550485A JP 2018518151 A5 JP2018518151 A5 JP 2018518151A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- acid sequence
- isolated
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 49
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 210000004027 cell Anatomy 0.000 claims description 37
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 150000007523 nucleic acids Chemical group 0.000 claims description 29
- 239000000523 sample Substances 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 21
- 108091007433 antigens Proteins 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 208000029742 colonic neoplasm Diseases 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 238000003364 immunohistochemistry Methods 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 230000011664 signaling Effects 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000000684 flow cytometry Methods 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 2
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 108091035707 Consensus sequence Proteins 0.000 claims description 2
- 241000282324 Felis Species 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 102000055298 human VTCN1 Human genes 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 238000000338 in vitro Methods 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139592P | 2015-03-27 | 2015-03-27 | |
| US62/139,592 | 2015-03-27 | ||
| PCT/US2016/024357 WO2016160620A2 (en) | 2015-03-27 | 2016-03-25 | Car t-cells for the treatment of b7-h4 expressing solid tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018518151A JP2018518151A (ja) | 2018-07-12 |
| JP2018518151A5 true JP2018518151A5 (enExample) | 2019-05-09 |
Family
ID=57007182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017550485A Withdrawn JP2018518151A (ja) | 2015-03-27 | 2016-03-25 | Ｂ７−ｈ４発現充実性腫瘍を処置するためのｃａｒ ｔ細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180118831A1 (enExample) |
| EP (1) | EP3274369A4 (enExample) |
| JP (1) | JP2018518151A (enExample) |
| CN (1) | CN107531782A (enExample) |
| AU (1) | AU2016243126A1 (enExample) |
| CA (1) | CA2981143A1 (enExample) |
| IL (1) | IL254700A0 (enExample) |
| WO (1) | WO2016160620A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10814011B1 (en) | 2017-06-16 | 2020-10-27 | Nantbio, Inc. | Anti-B7-H4 antibodies and methods |
| AU2018292181B2 (en) | 2017-06-30 | 2025-04-10 | Cellectis | Cellular immunotherapy for repetitive administration |
| CR20200138A (es) | 2017-08-25 | 2020-06-14 | Five Prime Therapeutics Inc | Anticuerpos de b7-h4 y métodos para usarlos |
| CN107903326B (zh) * | 2018-01-02 | 2020-06-30 | 广东省人民医院(广东省医学科学院) | 包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物 |
| CA3089246A1 (en) * | 2018-02-11 | 2019-08-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof |
| CA3091174A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| EP3759142A1 (en) | 2018-03-02 | 2021-01-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| CN112638949B (zh) * | 2019-03-21 | 2023-04-28 | 苏州鑫康合生物医药科技有限公司 | 抗b7s1多肽及其用途 |
| WO2021021213A1 (en) * | 2019-08-01 | 2021-02-04 | Nantkwest, Inc. | Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells |
| US20230192807A1 (en) * | 2020-05-15 | 2023-06-22 | Precision Biosciences, Inc. | Methods for immunotherapy |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CN113156120B (zh) * | 2021-03-26 | 2022-03-25 | 中国医学科学院北京协和医院 | B7h4在制备子宫内膜癌分子分型试剂及系统中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6468546B1 (en) * | 1998-12-17 | 2002-10-22 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
| EP2465872A3 (en) * | 2004-10-25 | 2012-12-19 | Merck Sharp & Dohme Corporation | Anti-ADDL antibodies and uses thereof |
| US7858752B2 (en) * | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| JP5941841B2 (ja) * | 2009-05-26 | 2016-06-29 | アイカーン スクール オブ メディシン アット マウント サイナイ | 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 |
| US9422351B2 (en) * | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| US9376485B2 (en) * | 2012-02-29 | 2016-06-28 | The Brigham And Women's Hospital, Inc. | Neutralizing antibody for epstein barr virus-associated disease |
| AU2013329311A1 (en) * | 2012-10-09 | 2015-04-30 | Igenica Biotherapeutics, Inc. | Anti-C16orf54 antibodies and methods of use thereof |
| WO2014100439A2 (en) * | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
| US10150813B2 (en) * | 2013-03-14 | 2018-12-11 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| WO2015025825A1 (ja) * | 2013-08-23 | 2015-02-26 | 学校法人藤田学園 | インフルエンザウイルスに対する抵抗力の判定方法 |
-
2016
- 2016-03-25 JP JP2017550485A patent/JP2018518151A/ja not_active Withdrawn
- 2016-03-25 CA CA2981143A patent/CA2981143A1/en not_active Abandoned
- 2016-03-25 EP EP16773873.1A patent/EP3274369A4/en not_active Withdrawn
- 2016-03-25 US US15/561,968 patent/US20180118831A1/en not_active Abandoned
- 2016-03-25 CN CN201680024423.4A patent/CN107531782A/zh active Pending
- 2016-03-25 AU AU2016243126A patent/AU2016243126A1/en not_active Abandoned
- 2016-03-25 WO PCT/US2016/024357 patent/WO2016160620A2/en not_active Ceased
-
2017
- 2017-09-26 IL IL254700A patent/IL254700A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018511319A5 (enExample) | ||
| JP2018518151A5 (enExample) | ||
| WO2020107715A1 (en) | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof | |
| Fisher et al. | Generation and preclinical characterization of an antibody specific for SEMA4D | |
| KR102346988B1 (ko) | 항 b7-h4 항체 | |
| TWI878541B (zh) | 抗ｃｌｄｎ１８.２抗體及其診斷用途 | |
| JP2012012402A5 (enExample) | ||
| CN112189021A (zh) | 抗b7-h3抗体及其用途 | |
| JP2018524973A5 (enExample) | ||
| JP2018518152A5 (enExample) | ||
| CN111995682B (zh) | 抗人SIRPα单克隆抗体及其用途 | |
| JP2013506428A5 (enExample) | ||
| JP2014527398A5 (enExample) | ||
| TW201829467A (zh) | 抗ｃｄ３抗體及含有該抗體的分子 | |
| JP2018505681A5 (enExample) | ||
| CN113683697B (zh) | 抗b7-h3抗体、其制备方法及用途 | |
| JP2020513769A (ja) | 抗ｌａｉｒ１抗体およびその使用 | |
| WO2014068300A1 (en) | Anti-s100a4 antibody molecules and their uses | |
| WO2021097800A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| CN111620949A (zh) | 结合人lag-3的抗体、其制备方法和用途 | |
| JP2021505663A5 (enExample) | ||
| WO2018162944A1 (en) | Recombinant antibodies to programmed death 1 (pd-1) and uses therefor | |
| TW202233677A (zh) | Bcma/taci抗原結合分子 | |
| WO2014192974A1 (ja) | 抗ｌｇｒ６抗体を含む癌の検出用又は診断用試薬 | |
| JP7082112B2 (ja) | 抗ｇｐｒ２０抗体 |